Thalidomide-O-amido-C8-NH2 is a high-purity E3 ligase ligand-linker conjugate engineered for advanced PROTAC (Proteolysis Targeting Chimera) research and drug development. This compound features thalidomide, a well-characterized cereblon (CRBN) ligand, covalently linked to an eight-carbon (C8) amido-terminated flexible spacer (NH2). It serves as an essential building block for the design and synthesis of PROTAC molecules, enabling the targeted degradation of disease-associated proteins through the ubiquitin-proteasome system. As an E3 ligase ligand-linker conjugate, Thalidomide-O-amido-C8-NH2 facilitates the recruitment of CRBN E3 ligase to target proteins, promoting their ubiquitination and subsequent proteasomal degradation. This reagent is ideal for researchers developing targeted protein degradation therapeutics, exploring novel drug modalities, or screening for PROTAC efficacy in oncology, neurodegenerative diseases, and other therapeutic areas.
Structure of 1950635-15-0
Quality Assurance
Worldwide Delivery
24/7 Customer Support
Category
E3 Ligase Ligand-Linker Conjugate
Molecular Formula
C23H30N4O6
Molecular Weight
458.51
* For research and manufacturing use only. Not for human or clinical use.
Size
Price
Stock
Quantity
--
$--
In stock
Looking for different specifications? Click to request a custom quote!
Thalidomide-O-amido-C8-NH2 is a specialized bifunctional molecule employed as a building block in the synthesis of PROTACs (Proteolysis Targeting Chimeras) and molecular glues. Featuring a thalidomide-derived E3 ligase ligand connected via an amide bond to a C8 alkyl linker terminated with an amine group, this conjugate is designed for high compatibility with various reactive groups during PROTAC assembly. Its tailored structure enables researchers to efficiently create compounds that harness targeted protein degradation, a powerful therapeutic strategy being explored in drug discovery.
Mechanism
The mechanism of Thalidomide-O-amido-C8-NH2 centers on targeted protein ubiquitination and degradation via the ubiquitin-proteasome system. The thalidomide moiety specifically binds to the cereblon (CRBN) E3 ubiquitin ligase, an essential component of the CRL4^CRBN complex. The terminal amine group on the C8 linker allows for conjugation with other active molecules, typically a ligand for a target protein. When incorporated into a PROTAC molecule, the construct simultaneously binds the target protein and cereblon E3 ligase, promoting proximity-induced ubiquitination of the target protein, which is subsequently recognized and degraded by the proteasome.
Applications
Thalidomide-O-amido-C8-NH2 is primarily used in the construction of cereblon-based PROTACs for targeted protein degradation. Its robust, adaptable linker enables efficient synthesis of bifunctional molecules tailored to degrade disease-relevant proteins implicated in cancer, neurodegenerative disorders, and autoimmune diseases. Additionally, this conjugate finds value in chemical biology research, enabling drug target validation and mechanistic studies of protein function. It supports the rapid prototyping and optimization of next-generation therapeutics and research tools designed for selective protein knockdown and functional modulation in living cells.
• Flexible C8 linker improves spatial orientation for efficient CRBN E3 ligase recruitment in PROTAC design.
• Amine-terminated structure enables straightforward conjugation to diverse warheads, streamlining PROTAC synthesis.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
CAS No.: 1950635-15-0
